# Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

> **NCT01010945** · PHASE1 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** erlotinib
- **DRUG:** gemcitabine
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT01010945
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-03
- **Primary completion:** 2012-01-25
- **Final completion:** 2012-01-25
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010945, "Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01010945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*